The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Khachanova N.V.

Pirogov Russian National Research Medical University;
City Clinical Hospital No. 24

Highly active multiple sclerosis: options for monoclonal antibody therapy

Authors:

Khachanova N.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10‑2): 49‑57

DOI: 10.17116/jnevro201911910249

Read: 11224 times

Download PDF (RU)
Contact the author
Table of contents

HIGHLY ACTIVE MULTIPLE SCLEROSIS: OPTIONS FOR MONOCLONAL ANTIBODY THERAPY
HIGHLY ACTIVE MULTIPLE SCLEROSIS: OPTIONS FOR MONOCLONAL ANTIBODY THERAPY

To cite this article:

Khachanova NV. Highly active multiple sclerosis: options for monoclonal antibody therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10‑2):49‑57. (In Russ.)
https://doi.org/10.17116/jnevro201911910249

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Glial fibrillary acidic protein: is there a rela­tionship with the course of multiple scle­rosis and traumatic brain injury before the onset of multiple scle­rosis?. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):80-84
An indi­vidual approach to the diagnosis and treatment of an acute psychotic condition in a patient with a multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):97-102
Surgical treatment of seco­ndary trigeminal neuralgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):203-209
Effi­cacy and safety of topi­cal anti­biotic therapy in patients with acute exte­rnal bacterial otitis: resu­lts of a retrospective study. Russian Bulletin of Otorhinolaryngology. 2024;(6):24-27
Quality of life of patients with multiple scle­rosis in the Smolensk region. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):36-40
Open obse­rvational study with a retrospective analysis of the effi­cacy and tole­rability of aceclofenac in patients with acute non-specific low back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):99-105
Hormonal contraception methods and multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30
Epidemiology of multiple scle­rosis in the city of Novo­sibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127
On the issue of choosing anesthesia methods: a comparison of gene­ral medi­cine and clinical dentistry. Stomatology. 2025;(1):76-80
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
Abstract:

The clinical course of multiple sclerosis (MS) is characterized by great variability. «Aggressive» MS, a concept used in the last 10 years, is associated with atypical course of the disease, which is manifested by more frequent exacerbations, the rapid increase in disability and pronounced signs of radiological activity according to MRI. The review presents data on the effectiveness of three monoclonal antibody drugs — natalizumab, alemtuzumab and ocrelizumab. In addition, updated data on the safety of monoclonal antibodies are presented to help the physician make a balanced choice of a drug and therapy strategy.

Keywords:

multiple sclerosis
escalation
induction
aggressive
monoclonal antibody
safety

Authors:

Khachanova N.V.

Pirogov Russian National Research Medical University;
City Clinical Hospital No. 24

Close metadata

References:

  1. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15:545-558. https://doi.org/10.1038/nri3871
  2. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126(4):770-782. https://doi.org/10.1093/brain/awg081
  3. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. 1989;112(6):1419-1428. https://doi.org/10.1093/brain/112.6.1419
  4. Kantarci O, Siva A, Eraksoy M, Karabudak R, Sutlas N, Agaoglu J, Turan F, Ozmenoglu M, Torgul E, Demirkiran M. Survival and predictors of disability in Turkish multiple sclerosis patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology. 1998;51:765-772. https://doi.org/10.1212/wnl.51.3.765
  5. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain. 2010;133(7):1914-1929. https://doi.org/10.1093/brain/awq118
  6. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. 1980;103:281-300. https://doi.org/10.1093/brain/103.2.281
  7. Menon S, Shirani A, Zhao Y, Oger J, Traboulsee A, Freedman MS, Tremlet H. Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:1192-1198. https://doi.org/10.1136/jnnp-2013-304951
  8. Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol. 2015;11:379-389. https://doi.org/10.1038/nrneurol.2015.85
  9. Freedman M, Rush C. Severe, highly active or aggressive multiple sclerosis. Continuum: Lifelong Learning in Neurology. 2016;22(3):761-784. https://doi.org/10.1212/CON.0000000000000331
  10. Devonshire V, Havrdova E, Radue EW, O’Connor P, Zhang-Auberson L, Agoropoulou C, Haring DA, Francis G, Kappos L, FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomized, placebo-controlled FREEDOMS study. Lancet Neurol. 2012;11:420-428. https://doi.org/10.1016/S1474-4422(12)70056-X
  11. Fazekas F, Bajenaru O, Berger T, Fabjan TH, Ledinek AH, Jakab G, Komoly S, Kobys T, Kraus J, Kurca E, Kyriakides T, Lisy L, Milanov I, Nehrych T, Moskovko S, Panayiotou P, Jazbec SS, Sokolova L, Talab R, Traykov L, Turcani P, Vass K, Vella N, Voloshyna N, Havrdova E. How does fingolimod (Gylenia) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? Front Neurol. 2013;4:10. https://doi.org/10.3389/fneur.2013.00010
  12. Derfuss T, Bergvall NK, Sfikas N, Tomic DL. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis. Curr Med Res Opin. 2015;31(9):1687-1691. https://doi.org/10.1185/03007995.2015.1067191
  13. Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O’Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL investigators. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009;256(3):405-415. https://doi.org/10.1007/s00415-009-0093-1
  14. Krieger S, Arnold DL, Cohen J, Coles AJ, Confavreux C, Fox E, Hartung HP, Havrdova E, Selmaj K, Weiner TH, Miller T, Twyman C, Lake S, Margolin D, Panzara M, Compston A. Alemtuzumab is efficacious in highly active RRMS patients in CARE-MS II. Abstract DX01. Presented at Joint Consortium of Multiple Sclerosis Centers (CMSC)/Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting; 2013.
  15. Krieger S, Singer B, Freedman MS, Lycke J, Berkovich R, Margolin D, Thangavelu K, Havrdova E. Treatment-naive patients with highly active RRMS demonstrated durable efficacy with alemtuzumab over 5 years. Neurology. 2016;86(suppl 16):51003.
  16. Davydovskaya MV, Khachanova NV, Evdoshenko EP, Pronin IN, Boyko AN, Zakharova MN, Alifirova VM, Turova EL, Malkova NA, Sivertseva SA, Tsukurova LA, Skoromets AA, Solodun IU. Recommendations on the algorithms for drug choice and risk management plan in the treatment of patients with remitting multiple sclerosis with natalizumab. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2016;116(10-2):79-97. (In Russ.) https://doi.org/10.17116/jnevro201611610279-97
  17. Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord. 2015;8(1):31-45. https://doi.org/10.1177/1756285614563522
  18. Hauser SL, Comi G, Hartung HP, Selmaj K, Traboulsee A, Bar-Or A, Arnold DL, Klingelschmitt G, Kakarieka A, Lublin F, Garren H, Kappos L, on behalf of the OPERA I and II clinical investigators. Efficacy and safety of ocrelizumab in relapsing multiple sclerosis — results of the interferon-beta-1a-controlled, double-blind, phase III OPERA I and II studies. Abstract 190. Mult Scler J. 2015;21(11):61-62.
  19. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O’Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. The Lancet Neurology. 2009;8(3):254-260. https://doi.org/10.1016/s1474-4422(09)70021-3
  20. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178. https://doi.org/10.1056/NEJMra052603
  21. Lazibat I, Nevajda B, Grahovac G, Brinar V. Should MS be treated by Escalation or Induction therapy? Coll Antropol. 2014;38(1):385-393.
  22. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7(1):21-39. https://doi.org/10.1038/nrd2399
  23. Rotstein DL, Healy BC, Malik MT, Chitnis MD, weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72(2):152-158. https://doi.org/10.1001/jamaneurol.2014.3537
  24. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 intergrin. Nature. 1992;356(6364):63-66. https://doi.org/10.1038/356063a0
  25. Krumbholz M, Derfuss T, Hohlfeld R, Meinl E. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol. 2012;8:613-623. https://doi.org/10.1038/nrneurol.2012.203
  26. del Pilar MM, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-DeMasters BK, Stüve O. Decrease in the numbers of dendritic cells and CD4+ T cells in central perivascular spaces due to natalizumab. Arch Neurol. 2008;65(12):1596-1603. https://doi.org/10.1001/archneur.65.12.noc80051
  27. Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, Trigueiro M, Racicot D, Guerette C, Antel JP, Fournier A, Grand’Maison F, Bar-Or A. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol. 2006;59(5):748-754. https://doi.org/10.1002/ana.20859
  28. Stüve O. The effects of natalizumab on the innate and adaptive immune system in the central nervous system. Journal of the Neurological Sciences. 2008;274(1-2):39-41. https://doi.org/10.1016/j.jns.2008.03.022
  29. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923. https://doi.org/10.1056/NEJMoa044396
  30. Bielekova B, Becker BL. Monoclonal antibodies in MS: mechanisms of action. Neurology. 2010;74(suppl 1):31-40. https://doi.org/10.1212/WNL.0b013e3181c97ed3
  31. Redpath S, Michaelsen T, Sandlie I, Clark MR. Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52. Immunology. 1998;93(4):595-600. https://doi.org/10.1046/j.1365-2567.1998.00472.x
  32. Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128(2):260-270. https://doi.org/10.1111/j.1365-2567.2009.03115.x
  33. Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, Compston DA, Coles AJ. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005;35(11):3332-3342. https://doi.org/10.1002/eji.200535075
  34. Ruck T, Afzali AM, Lukat KF, Eveslage M, Gross CC, Pfeuffer S, Bittner S, Klotz L, Melzer N, Weindl H, Meuth SG. ALAIN01 — Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential. BMC Neurology. 2016;16:34. https://doi.org/10.1186/s12883-016-0556-9
  35. Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G, Compston DA, Fahey MT, Coles AJ. Long-term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83:298-304. https://doi.org/10.1136/jnnp-2011-300826
  36. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786-1801. https://doi.org/10.1056/NEJMoa0802670
  37. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox E, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara M, Compston AS. FRCP for the CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized controlled phase 3 trial. Lancet. 2012;380:1829-1839. https://doi.org/10.1016/S0140-6736(12)61768-1
  38. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet. 2012;380:1819-1828. https://doi.org/10.1016/S0140-6736(12)61769-3
  39. Krieger S, Lubetzki C, Palmer J, Margolin D. Alemtuzumab reduces disease activity in treatment-naive patients with highly active relapsing-remitting multiple sclerosis. Mult Scler 2014, P088. Presented at Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) — European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting; 2014.
  40. Singer B, Krieger S, Berkovich R, Freedman MS, Margolin DH, Kasten L, Havrdova E. Patients who had highly active RRMS and an inadequate response to prior therapy demonstrated durable efficacy with alemtuzumab: 5-year follow-up of the CARE-MS II study. Neurology. 2016;86(suppl 16):164.
  41. Alifirova VM, Bisaga GN, Boyko AN, Bryukhov VV, Davydovskaya MV, Zakharova MN, Zakharova EV, Malkova NA, Popova EV, Salogub GN, Sivertseva SA, Troshina EA, Khachanova NV, Schmidt TE. Clinical recommendations for the use of alemtuzumab (Lemtrada). Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(2-2):115-126. (In Russ.) https://doi.org/10.17116/jnevro201711722115-126
  42. McCall B. Alemtuzumab to be restricted pending review, says EMA. Lancet Neurology. 2019;18:329-331. https://doi.org/10.1016/s0140-6736(19)30935-3
  43. Dalakas M. B cells as a therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurology. 2008;4(10):557-567. https://doi.org/10.1038/ncpneuro0901
  44. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a inRelapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221-234. https://doi.org/10.1056/NEJMoa1601277
  45. Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2017;10(1):51-66. https://doi.org/10.1177/1756285616666741
  46. Turner B, Cree BA, Kappos L, Montalban X, Papeix C, Wolinsky JS, Buffels R, Fiore D, Garren H, Han J, Hauser S. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol. 2019;266(5):1182-1193. https://doi.org/10.1007/s00415-019-09248-6
  47. Boyko AN, Davydovskaya MV, Khachanova NV, Zakharova MN, Spirin NN, Popova EV, Alifirova VM, Vlasov YaV, Sivertseva SA, Khabirov FA, Shumilina MV, Evdoshenko EP. Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3):16-25. (In Russ) https://doi.org/10.14412/2074-2711-2019-3-16-25
  48. Belousov UB, Gracianskaya AN. Postmarketing drug safety — pharmacovigilance. Lechebnoe Delo. 2007;2:17-22 (In Russ.)
  49. McGinley MP, Moss BP, Cohen JA. Safety of monoclonal antibodies for the treatment of multiple sclerosis. Expert Opinion on Drug Safety. 2016;1:89-100. https://doi.org/10.1080/14740338.2017.1250881
  50. Kleinschmidt-DeMasters B, Tyler K. Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis. New England Journal of Medicine. 2005;353(4):369-374. https://doi.org/10.1056/nejmoa051782
  51. Bozic C, Subramanyam M, Richman S, Plavina T, Zhang A, Ticho B. Anti-JC virus ( JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. Eur J Neurol. 2014;21(2):299-304. https://doi.org/10.1111/ene.12304
  52. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880. https://doi.org/10.1056/NEJMoa1107829
  53. Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Annals of Neurology. 2014;76(6):802-812. https://doi.org/10.1002/ana.24286
  54. Khachanova NV, Davydovskaya MV, Evdoshenko EP. Updated risk stratification and risk management plan for Natalizumab-associated progressive multifocal leukoencephalopathy. RMJ. 2017;13:3-7. (In Russ.).
  55. D’Amico E, Zanghi A, Leone C, Tumani H, Patti F. Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs. Drug Saf. 2016;39(12):1163-1174. https://doi.org/10.1007/s40264-016-0461-6
  56. Dong-Si T, Gheuens S, Gangadharan A, Wenten M, Philip J, McIninch J, Datta S, Richert N, Bozic C, Bloomgren G, Richman S, Weber T, Clifford DB. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.J Neurovirol. 2015;21(6):637-644. https://doi.org/10.1007/s13365-015-0316-4
  57. O’Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76:1858-1865. https://doi.org/10.1212/WNL.0b013e31821e7c8a
  58. Fox RJ, Cree BA, De Seze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalban X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duta P, RESTORE. MS disease activity in RESTORE: a randomzed 24-week natalizumab treatment interruption study. Neurology. 2014;82(17):1491-1498. https://doi.org/10.1212/WNL.0000000000000355
  59. Iaffaldano P, Lucisano G, Pozzilli C, Morra B, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferro MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Sacca F, Baroncini D, Comi G, Trojano M. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain. 2015;138(11):3275-3286. https://doi.org/10.1093/brain/awv260
  60. Kappos L, Radue EW, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung HP, Derfuss T, Naegelin Y, Sprenger T, Mueller-Lenke N, Griffiths S, Rosenstiel P, Gottschalk R, Zhang Y, Dahlke F, Tomic D. On behalf of the TOFINGO study group. Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS. Neurology. 2015;85:29-39. https://doi.org/10.1212/WNL.0000000000001706
  61. Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T. on behalf of the Austrian MS Treatment Registry (AMSTR). Switching from natalizumab to ngolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry. J Neurol. 2019;16:1-6. https://doi.org/10.1007/s00415-019-09464-0
  62. Malucchi S, Capobianco M, Lo Re M, Malentacchi M, di Sapio A, Matta M, Sperli F, Bertolotto A. High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: An Observational Study. Neurol Ther. 2017;6:145. https://doi.org/10.1007/s40120-016-0058-0
  63. John N, Carroll A, Brownlee WJ, Chataway J. Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. 2019. Published Online First: 11 May 2019. https://doi.org/10.1136/jnnp-2019-320687
  64. Giovannoni G, Marta M, Davis A, Turner B, Gnanapavan S, Schmierer K. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Practical Neurology. 2016;16:389-393. https://doi.org/10.1136/practneurol-2015-001355
  65. Costelloe L, Jones J, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother. 2012;12(3):335-341. https://doi.org/10.1586/ern.12.5
  66. Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci. 2015;16(7):16414-16439. https://doi.org/10.3390/ijms160716414
  67. Graf J, Aktas O, Rejdak K, Hartung HP. Monoclonal Antibodies for Multiple Sclerosis: An Update. BioDrugs. 2019;33(1):61-78. https://doi.org/10.1007/s40259-018-0327-9
  68. Khachanova NV, Bakhtiyarova KZ, Boyko AN, Vlasov YaV, Davydovskaya MV, Evdoshenko EP, Zakharova MN, Malkova NA, Sivertseva SA, Spirin NN, Stolyarov ID, Schmidt TE, Khabirov FA. Provision of alemtuzumab safety is one of the main components of pharmacovigilance. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;118(8-2):81-86. (In Russ.) https://doi.org/10.17116/jnevro201811808282
  69. Gerevini S, Capra R, Bertoli D, Sottini A, Imberti L. Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy. Mult Scler J. 2019;25(8):1196-1201. https://doi.org/10.1177/1352458519832259
  70. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209-220. https://doi.org/10.1056/NEJMoa1606468
  71. Mayer L, Kappos L, Racke MK, Rammohan K, Traboulsee A, Hauser SL, Julian L, Kondgen H, Li C, Napieralski J, Zheng H, Wolinsky JS. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord. 2019;30:236-243. https://doi.org/10.1016/j.msard.2019.01.044
  72. Luciani K, Katz J, Lathi E, Geils HM. ACAPELLA: Real-world experience with ocrelizumab: an observational study evaluating safety in patients with relapsing and progressive multiple sclerosis. Presented at the Consortium of Multiple Sclerosis Centers Annual Meeting in Nashville, TN; May 30—June 2, 2018. Poster (DX22). Int J MS Care. 2018;20(suppl 1):24.
  73. Bigaut K, Seze JD, Collongues N. Ocrelizumab for the treatment of multiple sclerosis. Expert Review of Neurotherapeutics. 2019;19(2):97-108. https://doi.org/10.1080/14737175.2019.1561284
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.